Compare Carlyle Group Inc (CG) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs Revvity Inc — how do they compare? Carlyle Group Inc trades at $48.27 (market cap $17.23B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Carlyle Group Inc is the larger of the two by market cap, and Carlyle Group Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| CG | RVTY | |
|---|---|---|
Market Cap | $17.23B | $12.91B |
Sector | Financials | Technology |
52-Week High | $69.35 | $117.75 |
52-Week Low | $40.52 | $82.26 |
Dividend Yield | 2.9% | 0.24% |
Enterprise Value | — | $15.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CG trades at $48.14, up 0.71% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat estimates, with revenue growth and AUM expansion noted. The stock shows positive momentum near key resistance at $50, supported by institutional buying and strategic partnerships.
Outlook is positive given earnings beats and a $59.14 consensus price target, but risks include volatile cash flows and high P/E of 50.36. Investment appeal hinges on sustained fundraising and execution amid economic uncertainty.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
